Response and Discontinuation Rates of Newer Anti-depressants: A Meta-Analysis of Randomized Controlled Trials in Treating Depression

Journal of the Medical Association of Thailand

Volumn 81, Issue 6, 1998, Pages

  Srisurapanont, Manit ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; MIRTAZAPINE; NEFAZODONE; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; DRUG WITHDRAWAL; HUMAN; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHI-SQUARE DISTRIBUTION; CONFIDENCE INTERVALS; DEPRESSION; EVALUATION STUDIES; HUMANS; ODDS RATIO; RANDOMIZED CONTROLLED TRIALS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 18544404952     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Song F, Freemantle N, Sheldon TA, House A, Watson P, Long A. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683-7.
2. Montgomery SA, Henry J, McDonald G, et al. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 1994; 9: 47-53.
3. Anderson IM, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995; 310: 1433-8.
4. Hotopf M, Hardy R, Lewis G. Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 1997; 170: 120-7.
5. Richelson E (1994) The pharmacology of anti-depressants at the synapse: focus on newer compounds. J Clin Psychiatry 1994; 9 (Suppl A): 34-9.
6. de Boer T, Ruigt GSF. The selective α2- adreno-reptor antagonist mirtazapine (Org 3770) enhances noradrenergic and 5-HT1A-mediated serotonergic neurotransmission. CNS Drugs 1995; 4 (Suppl 1): 29-38.
7. Nemeroff CB. Evolutionary trends in the pharmacotherapeutic management of depression. J Clin Psychiatry 1994; 55 (Suppl 12): 3-15.
8. Feighner JP, Pambakian R, Fowler RC, Boyer WF, D'Amico MF. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression. Psychopharmacol Bull 1989; 25: 219-21.
9. Fontaine R, Ontiveros A, Elie R, et al. A double-blind comparison of nefazodone, imipramine, and placebo in major depression. J Clin Psychiatry 1994; 55: 234-41.
10. Rickels K, Schweizer E, Clary C, Fox I, Weise C. Nefazodone and imipramine in major depression: a placebo-controlled trial. Br J Psychiatry 1994; 164: 802-5.
11. Ansseau M, Darimont P, Lecoq A, et al. Controlled comparison of nefazodone and amitriptyline in major depressive inpatients. Psychopharmacology 1994; 115: 254-60.
12. Rickels K, Robinson DS, Schweizer E, Marcus RN, Roberts DL. Nefazodone: aspects of efficacy. J Clin Psychiatry 1995; 56 (Suppl 6): 43-6.
13. Cohn CK, Robinson DS, Roberts DL, Schwiderski UE, O'Brien K, Ieni JR. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression. J Clin Psychiatry 1996; 57 (Suppl 2): 15-8.
14. Baldwin DS, Hawley CJ, Abed RT, et al. A multicenter double-blind comparison of nefazodone and paroxetine in the treatment of outpatients with moderate-to-severe depression. J Clin Psychiatry 1996; 57 (Suppl 2): 46-52.
15. Feiger A, Kiev A, Shrivastava RK, Wisselink PG, Wilcox CS. Nefazodone versus sertraline in out-patients with major depression: focus on efficacy, tolerability, and effects on sexual function and satisfaction. J Clin Psychiatry 1996; 57 (Suppl 2): 53-62.
16. Cunningham LA, Borison RL, Carman JS, et al. A comparison of venlafaxine, trazodone, and placebo in major depression. J Clin Psychopharmacol 1994; 14: 99-106.
17. Schweizer E, Feighner J, Mandos LA, Rickels K. Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients. J Clin Psychiatry 1994; 55: 104-8.
18. Clerc GE, Ruimy P, Verdeau-Pailles J on behalf of the Venlafaxine French Inpatient Study Group. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994; 9: 139-43.
19. Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990; 26: 191-6.
20. van Moffaert M, de Wilde J, Vereecken A, et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. Int Clin Psychopharmacol 1995; 10: 3-9.
21. Zivkov M, de Jongh GD. Org 3770 versus amitriptyline: a 6-week randomized double-blind multicenter trial in hospitalized depressed patient. Human Psychopharmacology 1995; 10: 173-80.
22. Bremmer JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995; 56: 519-25.
23. Tehrani E, Krussel J, Borg L, Munk-Jorgensen P. Dropping out of psychiatric treatment: a prospective study of a first-admission cohort. Acta Psychiatr Scand 1996; 94: 266-71.
24. Fleiss JL. Confidential intervals for the odds ratio in case-control studies: the state of the art. J Chron Dis 1979; 32: 69-77.
25. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York: Wiley, 1981.
26. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovas Dis 1985; 5: 335-71.
27. Laupacis N, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Eng J Med 1988; 318: 1728-33.
28. Levine M, Walter S, Lee H, Haines T, Holbrook A, Moyer V, for the Evidence-Based Medicine Working Group. User's guides to the medical literature. IV. How to use an article about harm. JAMA 1994; 271: 1615-9.